(29 days)
The Nova StatStrip Glucose Hospital Meter System is intended for in vitro diagnostic use by health care professionals and for Point-Of-Care usage for the quantitative measurement of glucose in capillary, venous, arterial, and neonate whole blood. It is indicated for use in a clinical setting by healthcare professionals as an aid to monitor the effectiveness of diabetes control.
Nova StatStrip Glucose Test Strips are intended for use only with the StatStrip Glucose Hospital Meter for quantitative tests. The glucose meter is intended to quantitatively measure glucose (sugar) in whole blood. The Glucose Meter is calibrated to provide plasma equivalent results to laboratory methods. Nova StatStrip Glucose Test Strips are for testing outside the body (in vitro diagnostic use only).
Nova StatStrip Control Solutions is intended for use with the Nova StatStrip Glucose Hospital Meter and Nova StatStrip Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results. There are three levels of controls, (Level 2, and Level 3). These solutions will be offered for sale separately from the meter.
Nova StatStrip Glucose Linearity Kit solutions are used to check the linearity of the Nova StatStrip Glucose Hospital Meter System. There are five levels of linearity solutions. (Level 2, Level 3. Level 4. and Level 5).
Not Found
The provided text is a 510(k) premarket notification letter from the FDA to Nova Biomedical Corp. for their Nova StatStrip Glucose Hospital Meter System. It acknowledges the submission and states that the device is substantially equivalent to legally marketed predicate devices. The letter primarily focuses on regulatory approval and indications for use.
Crucially, this document does not contain the detailed acceptance criteria for device performance, nor does it describe specific studies proving that the device meets such criteria. It lists the "Indications for Use" for the device, but these are about how the device is intended to be used, not its performance metrics like accuracy, precision, or detection limits.
Therefore, I cannot provide the requested information about acceptance criteria, device performance, study details (sample size, data provenance, expert qualifications, adjudication, MRMC, standalone performance), or ground truth establishment based solely on the text provided. This information would typically be found in the actual 510(k) submission document itself (which is not provided), or in a separate study report or technical documentation for the device.
§ 862.1345 Glucose test system.
(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.